At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 103 enrolled
Drug / intervention
QAW039 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study Evaluating Efficacy and Safety of QAW039 in the Treatment of Patients With Moderate to Severe Atopic Dermatitis
In Brief
A Phase 2 clinical trial evaluating QAW039 and Placebo for Atopic Dermatitis. Completed, enrolled 103 participants across 18 sites in 8 countries.
Detailed Summary
The purpose of this study is to determine whether QAW039 is safe and has beneficial effects in people who have moderate to severe atopic dermatitis (AD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesAustralia, Austria, Belgium, Bulgaria, Germany, Netherlands, Romania, South Africa
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedFeb 2013
Enrollment StartJun 2013
Primary CompletionNov 2014
TodayJul 2026
First PostedFeb 7, 2013
Enrollment StartJun 1, 2013
Primary CompletionNov 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 13.4 years ago
Interventions
QAW039drug
Capsules
Placebodrug
Capsules